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osting by EAbstract Background: To investigate the rate of all cause and cardiovascular mortality in patients
with symptomatic or asymptomatic peripheral arterial disease (PAD) compared to those without
PAD.
Methods and results: All the subjects were inpatients at high risk of atherosclerosis and enrolled
from February to November, 2006. A total of 320 were followed up until an end-point (death)
was reached or until February 2010. The mean follow-up time was 37.7 ± 1.5 months. Compared
with non-PAD, PAD patients had signiﬁcantly higher rates of hypertension, diabetes mellitus, and
smoking (P< 0.01). Those with symptomatic and asymptomatic PAD had a much higher all cause
(37.5% and 23.0% vs. 12.1%) and cardiovascular mortality (18.8% and 13.8% vs. 6.7%) compared
to those without PAD (P< 0.001). The symptomatic PAD patients were 1.831 times (95% CI:
1.222–2.741) as likely to die as those without PAD, and 1.646 times (95% CI: 1.301–2.083) in
asymptomatic PAD patients after adjusting for other factors. Those with symptomatic orpartment of Cardiology, Spe-




tian Society of Cardiology.
lsevier
8 E.M. Daoud et al.asymptomatic PAD were more than twice as likely to die of CVD as those without PAD (RR:
2.248, 95% CI: 1.366–3.698 and RR: 2.105, 95% CI: 1.566–2.831, respectively).
Conclusions: PAD was associated with a higher all cause and cardiovascular mortality whether or
not PAD is symptomatic.
ª 2011 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Peripheral arterial disease (PAD) caused by atherosclerotic
occlusion of leg arteries is an important manifestation of sys-
temic atherosclerosis. The prevalence of PAD is variable in dif-
ferent reports,1–6 but the average age-adjusted prevalence of
PAD is approximately 12%.7 Many trials have shown that
PAD was associated with considerable general and cardiovas-
cular (CV) morbidity and mortality. PAD prevalence of 25%
was reported in patients with coronary artery disease
(CAD).8 One US study estimated PAD prevalence of more
than 5 million adults. Patients with critical PAD face an an-
nual mortality rate of 25%, which is overwhelmingly due to
myocardial infarction and ischemic stroke.9 However, only
few patients present typical intermittent claudication which
can be diagnostic of PAD. Ankle-brachial index (ABI), a ratio
of ankle systolic blood pressure (SBP) to brachial systolic pres-
sure, is widely used in clinical practice to assess the potency of
the lower arterial system and to screen for PAD. The ABI
threshold of 0.9 has a sensitivity of 95% and a speciﬁcity of
100% compared with angiography.10 In 2006, our team ﬁrstly
began to investigate the baseline characteristics of PAD pa-
tients, who were followed-up for a mean period of 3 years to
ﬁnd the relationship between mortality and symptomatic or
asymptomatic PAD in Egyptian population.
2. Methods
2.1. Study design and participants
This study was designed in 2006 to investigate the risk factors
for PAD in Egyptian population, and the relationship between
mortality and symptomatic or asymptomatic PAD. All the
subjects were hospitalized patients over 35 years old with 2
or more CV risk factors and enrolled from Mansoura Univer-
sity Hospital and Mansoura Specialized Medicine Hospital
from February to November 2006. Risk factors included
smoking, diabetes mellitus (DM), hypertension, dyslipidemia,
stroke and history of CAD. Exclusion criteria included severe
heart failure, liver cell failure, renal failure or cancer. Finally, a
population of 372, agedP35 years, including 197 men and 175
women who had complete baseline data were included in the
cohort. They were followed up until an end-point (death)
was reached or until February 2010. The mean follow-up dura-
tion was 3 years (37.7 months) Informed consent was obtained
from all the participants.
2.2. ABI measurement
Doppler ultrasound was used to measure SBP on bilateral bra-
chial position, tibial and dorsal pedal arteries after at least 5
minutes of rest in the supine position. The Doppler probe
was used at a frequency of 5 MHz. The left or right ABI isthe ratio of the pressure on the left or right dorsal or posterior
tibial arteries to the higher brachial pressure. An ABI 6 0.9 in
either leg was considered as evidence of PAD.11
2.3. Diagnosis and classiﬁcation of PAD
The diagnosis of PAD was assessed by ABI measurements,
and the ABI 6 0.9 was used to diagnose PAD. Symptomatic
PAD was deﬁned as those whose ABI 6 0.9 and with a typical
intermittent claudication. Asymptomatic PAD was those
whose ABI 6 0.9 and without a typical intermittent claudica-
tion. Non-PAD was those with 0.9 < ABI 6 1.40.
2.4. Identiﬁcation of all-cause and CV death
Death was identiﬁed by hospitals’ records or by contacting the
participants’ families. Further causes of death were investi-
gated by using medical record and informant interviews. All
materials were reviewed independently to conﬁrm the cause
of death.
2.5. Statistical analysis
Values of continuous variables, such as age, SBP, diastolic
blood pressure, plasma glucose, total cholesterol, triglycerides,
high-density lipoprotein-cholesterol, and low-density lipopro-
tein-cholesterol were expressed as mean ± standard deviation
of mean. Categorical variables were expressed as percentages.
All the participants were classiﬁed into symptomatic PAD,
asymptomatic PAD or Non-PAD group. Independent-samples
ANVOA and the chi-square tests were used to compare con-
tinuous and categorical differences at baseline, respectively.
Kaplan–Meier model was employed to calculate the cumu-
lative mortality rate from all-cause and CV causes among the
three groups. Cox regression model was used to estimate the
independent association between PAD and all-cause and CV
mortality compared with Non-PAD, after adjusting for age,
gender, smoking, CAD, hypertension, stroke, DM, dyslipide-
mia and medications. A P-value of <0.05 was considered sig-
niﬁcant. All analyses were performed with SPSS (Statistics
Package for Social Science) version 16.0.
3. Results
A total of 372 participants with available baseline data were
enrolled in the cohort; of these, 96 participants (26.0%) were
diagnosed as PAD by ABI (19 patients with symptomatic
PAD and 77 with asymptomatic PAD) and 276 constituted
the non-PAD group (the baseline characteristics of all subjects
in the beginning of study are shown in Table 1). During a
mean follow-up time of 37.6 ± 1.5 months, 52 (14%) of all
the subjects were lost during the follow-up because of the
changes of telephone number or family address. Among those
Table 1 The characteristics of all patients at baseline in the beginning of study.
Baseline characters Symptomatic PAD (n= 19) Symptomatic PAD (n= 77) Non-PAD (n= 276) P-value
Age (years) 71.8 ± 8.7 71.6 ± 9.7 65.2 ± 11.1 <0.001
Gender (male, %) 52.3 48.5 54.4 <0.05
CAD (%) 64.8 60.6 52.3 <0.001
Hypertension (%) 87.6 77.7 70.4 <0.001
SBP (mmHg) 146.3 ± 25.8 142.4 ± 24.4 138.7 ± 22.9 <0.001
DBP (mmHg) 80.3 ± 14.1 80.8 ± 12.6 80.6 ± 12.8 <0.005
DM (%) 60.1 46.4 35.5 <0.001
Plasma glucose (mmol/L) 6.9 ± 3.0 6.7 ± 3.0 6.4 ± 2.8 <0.05
Dyslipidemia (%) 57.9 43.2 41.6 <0.01
TC (mmol/L) 4.7 ± 1.2 4.7 ± 1.2 4.6 ± 1.1 >0.05
TG (mmol/L) 1.7 ± 1.2 1.8 ± 1.5 1.7 ± 1.1 >0.05
LDL-C (mmol/L) 2.8 ± 0.9 2.7 ± 0.8 2.7 ± 1.5 >0.05
HDL-C (mmol/L) 1.1 ± 0.3 1.2 ± 0.4 1.2 ± 0.4 <0.05
Stroke (%) 61.7 51.9 38.3 <0.001
Smoking (%) 48.7 40.6 38.0 <0.05
Abbreviations: CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; TC, total
cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol.
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12 in the asymptomatic PAD group, and 37 in the non-PAD
group.
After careful calculation, the missing subjects did not signif-
icantly affect the major results of this study. There were 320
subjects with complete data after 3 years of follow-up. The pa-
tients with PAD were older than those without PAD
(71.8 ± 8.7 for symptomatic and 71.6 ± 9.7 for asymptomatic
PAD vs. 65.2 ± 11.1 for non-PAD, P< 0.001). Compared
with non-PAD, PAD patients with or without symptom had
signiﬁcantly higher morbidity of CAD, hypertension, DM,
dyslipidemia, stroke or smoking (all P< 0.01). Of the 320 par-
ticipants (16 with symptomatic PAD; 65 with asymptomatic
PAD and 239 without PAD) who had complete follow-up
data; 50 of them died including 28 patients who died of CV
causes. The number of all-cause deaths and CV deaths were
6 and 3, 15 and 9, 29 and 16 in symptomatic PAD, asymptom-
atic PAD and non-PAD group, respectively. The 3-year allFigure 1 Flow chart showing the cascade of events since thecause mortality in PAD patients was 26%. Fig. 1 is a ﬂow
chart which shows the cascade of events since the inclusion
of patients at baseline until the end of the study.
Table 2 demonstrates the incidence of all-cause and CV
mortalities among the three groups after 3 years follow-up.
Those with symptomatic PAD had a signiﬁcant highest
(P< 0.001) all cause (37.5%) and CV (18.8%) mortalities
among the three groups. The mortality was still signiﬁcantly
higher in PAD patients without symptom (23% for all-cause,
13.8% for CV causes) than in those without PAD (12% for
all-cause, 6.7% for CV causes; P< 0.001).
As shown in Figs. 2A and 2B, all cause and CV mortalities
were compared according to gender among the three groups.
No signiﬁcant differences of mortalities were found in male
or female PAD patients with or without symptom; but men
had slightly higher mortality than women in the non-PAD
group (14.2% vs. 10.0% for all cause mortality and 7.8% vs.
5.1% for CVD mortality, P< 0.05).inclusion of patients at baseline until the end of the study.
Table 2 The incidence of all-cause and cardiovascular mortalities among the three groups after 3 years follow-up.
Mortality Symptomatic PAD (n= 16) Asymptomatic PAD (n= 65) Non-PAD (n= 239) P-value
All-cause 6 (37.5%) 15 (23.0%) 29 (12.1%) <0.001
Cardiovascular 3 (18.8%) 9 (13.8%) 16 (6.7%) <0.001
Figure 2A All cause mortalities among the three groups after
3 years follow-up.
Figure 2B Cardiovascular mortalities among the three groups
after 3 years follow-up.
Figure 3A Univariate Kaplan–Meier curves for subjects among
the three groups for all-cause mortality after 3 years follow-up.
Figure 3B Univariate Kaplan–Meier curves for subjects among
the three groups for cardiovascular mortality after 3 years follow-
up.
10 E.M. Daoud et al.Figs. 3A and 3B illustrate the survival distribution of the
three groups for all-cause and CVD mortality, respectively.
The cumulate survival rates in patients with symptomatic or
asymptomatic PAD were signiﬁcantly lower than those with-
out PAD (log-rank test P< 0.001).
Figs. 4A and 4B showed the adjusted relative risk (RR) of
all cause and CV mortality in the three groups. The symptom-
atic PAD patients were 1.831 times (95% CI: 1.222–2.741) as
likely to die as those without PAD, and 1.646 times (95%
CI: 1.301–2.083) in asymptomatic PAD patients afterFigure 4A Relative risks of all cause mortality (adjusted for
gender, age, smoking, CAD, hypertension, stroke, DM, dyslipi-
demia and medications for those diseases) after 3 years follow-up.
Figure 4B Relative risks of cardiovascular mortality (adjusted
for gender, age, smoking, CAD, hypertension, stroke, DM,
dyslipidemia and medications for those diseases) after 3 years
follow-up.
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stroke, DM, dyslipidemia and medications for those diseases.
Those with symptomatic or asymptomatic PAD had more
than twice as likely to die of CV causes as those without
PAD (RR: 2.248, 95% CI: 1.366–3.698 and RR: 2.105, 95%
CI: 1.566–2.831, respectively) after adjusting for other factors.
4. Discussion
Atherosclerosis is a systemic disease, which is considered the
leading cause of death and waste of health resources in adults
worldwide. Recently, physicians tried to ﬁnd a predictor to
early identify atherosclerotic diseases. Epidemiological and
clinical trials have proved that PAD is widely accepted as an
indicator for generalized atherosclerosis, but PAD is quite of-
ten asymptomatic in older adults. However, trials showed that
both symptomatic and asymptomatic patients with PAD have
an increased mortality compared to those without PAD.12
Many trials have also shown ABI as a marker of PAD which
predicts CV and overall mortality. Stoffers et al.13 reported
that up to three-quarters of patients with PAD were asymp-
tomatic, but our results showed that four-ﬁfths of PAD pa-
tients are without typical symptoms.
The patients with PAD (whether or not symptomatic) were
older and more likely to have CAD, hypertension, DM, dysl-
ipidemia, stroke or smoking than those without PAD at base-
line (Table 1), a result similar to Newman’s former report.5
During the 3 years follow-up, there was a signiﬁcantly in-
creased tendency on all-cause mortality from non-PAD,
asymptomatic PAD to symptomatic PAD; and the same ap-
plies to CV mortality (Table 2). The all cause mortality was
37.5% in patients with symptomatic PAD, 23.0% in patients
with asymptomatic PAD, and 12.1% in patients without
PAD. Thus, the all cause mortality in patients with PAD
was 60.5%. Diehm et al reported that the 3 years all cause
mortality was 10.9% in patients with PAD.14 Our ﬁgures were
much higher, because our subjects were inpatients at high risk
of atherosclerosis. However, all those data highlighted that
PAD patients are at a very high risk of death. Diehm et al.15
further showed that the 5 years all cause mortality was24.1% in patients with symptomatic PAD, 19.2% in patients
with asymptomatic PAD (low ABI), and 9.5% in patients
without PAD; while others reported that the estimated ﬁve-
year mortality in patients with PAD was 30%.16,17
No signiﬁcant gender difference was found regarding all
cause mortality and CV mortality in symptomatic and asymp-
tomatic PAD groups; but male patients seemed to have a high-
er mortality than females. A striking increase in all cause and
CV mortality was seen in PAD groups, especially in the symp-
tomatic PAD one (Figs. 3A and 3B).
After adjusting for age, gender, smoking, CAD, hyperten-
sion, stroke, DM, dyslipidemia and medications by Cox
regression model, the symptomatic PAD patients were 1.831
times as likely to die as those without PAD, and 1.646 times
in asymptomatic PAD patients. The risk of death in patients
with symptomatic or asymptomatic PAD was more than 2-
fold higher than that of non-PAD.
In this study, we showed that the patients with asymptom-
atic PAD were still at high risk of death. Moreover, our re-
search and other reports proved that a low ABI is a strong
predictor of mortality during follow-up; even in patients with
no clinical symptoms of PAD.18,19 A recent meta-analysis also
showed that the measurement of the ABI may improve the
accuracy of CV risk prediction beyond the Framingham risk
score.20
Although PAD is highly prevalent, physician awareness
and detection of this disease is low8,21, perhaps the high rate
of asymptomatic disease is the most important reason.13
ABI was regarded as indicator of mortality for many years;
but in the whole strategy of atherosclerosis risk detection,
less attention has been paid to the measurement of ABI,
and – therefore – the presence of PAD has been underscored
or not recognized.21,22 Hence screening for PAD should be
performed routinely in all elderly patients and in the general
population who are at increased risk of subsequent CV
events.
Evaluation is now required for the potential of incorporat-
ing ABI measurement into CV prevention programs. PAD
should be aggressively treated just as coronary artery disease.23
All those measures should be applied to identify PAD in order
to reduce mortality.
There are several limitations to our study. Firstly, the
duration of follow-up is only 3 years, so that further study
should be done. Secondly, 14% of the subjects were lost
during the follow-up due to the changes of telephone num-
ber or home address. If not, we could get more precise re-
sults. Thirdly, all the subjects were inpatients at high risk
of atherosclerosis; so that our study cannot represent the
general population in Egypt.
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